Advertisement

Drugs

, Volume 70, Issue 17, pp 2281–2288 | Cite as

Fentanyl Sublingual

In Breakthrough Pain in Opioid-Tolerant Adults with Cancer
  • Claudine M. Chwieduk
  • Kate McKeage
Adis Drug Profile

Abstract

Fentanyl is a potent opioid with a short duration of action. Fentanyl sublingual has been formulated as a rapidly disintegrating tablet that is quickly absorbed, producing a fast onset of analgesia.

In two randomized, double-blind clinical trials, fentanyl sublingual as single fixed or titrated doses reduced pain intensity during breakthrough pain episodes to a significantly greater extent than placebo in opioid-tolerant cancer patients.

In a fixed-dose phase II trial and a titrated-dose phase III trial, fentanyl sublingual (as a single 400 μg dose and as titrated doses) reduced mean pain intensity difference (PID) to a significantly greater extent than placebo over the entire treatment period (up to 60 minutes), reaching statistical significance 15 minutes post-dose.

In the titrated-dose study, the mean sum of PID (area under the PID vs time curve) at 30 minutes post-dose was significantly greater with fentanyl sublingual than placebo, with significant improvements in PID seen at 10 minutes maintained at 60 minutes post-dose.

In the phase III study, patients receiving fentanyl sublingual were more satisfied with their treatment than patients receiving placebo (measured using the Patient Global Evaluation of Medication score), and almost half of all fentanyl sublingual recipients were satisfied or very satisfied with their treatment.

Fentanyl sublingual was generally well tolerated in the two trials and most adverse events were mild to moderate in intensity.

Keywords

Fentanyl Breakthrough Pain Primary Efficacy Variable Pain Intensity Difference Sublingual Mucosa 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements and Disclosures

The manuscript was reviewed by: H. Lennernäs, Department of Pharmacy, Uppsala University, Uppsala, Sweden; S. Mercadante, Department of Pain Relief and Palliative Care, La Maddalena Cancer Center, Palermo, Italy.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was also offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

References

  1. 1.
    Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999 May; 81(1–2): 129–34PubMedCrossRefGoogle Scholar
  2. 2.
    Fine PG. Breakthrough cancer pain: epidemiology, characteristics and management. CNS Drugs 2000 May; 13: 313–9CrossRefGoogle Scholar
  3. 3.
    Miaskowski C, Cleary J, Burney R, et al. American Pain Society guideline for the management of cancer pain in adults and children [online]. Available from URL: http://www.guidelines.gov/summary/summary.aspx?doc_id=7297 [Accessed 2010 Oct 11]
  4. 4.
    Scottish Intercollegiate Guidelines Network. Control of pain in adults with cancer [online]. Available from URL: http://www.sign.ac.uk/pdf/qrg106.pdf [Accessed 2010 Oct 11]
  5. 5.
    Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999 May 15; 353(9165): 1695–700PubMedCrossRefGoogle Scholar
  6. 6.
    Mercadante S, Fulfaro F. World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 2005 May; 16 Suppl.: iv132–5PubMedCrossRefGoogle Scholar
  7. 7.
    Hanks GW, de Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001 Mar 2; 84(5): 587–93PubMedCrossRefGoogle Scholar
  8. 8.
    Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of Great Britain and Ireland. Eur J Pain 2009 Apr; 13(4): 331–8PubMedCrossRefGoogle Scholar
  9. 9.
    Christrup LL, Lundorff L, Werner M. Novel formulations and routes of administration for opioids in the treatment of breakthrough pain. Therapy 2009; 6(5): 695–706CrossRefGoogle Scholar
  10. 10.
    Blick SKA, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006; 66(18): 2387–93PubMedCrossRefGoogle Scholar
  11. 11.
    William L, MacLeod R. Management of breakthrough pain in patients with cancer. Drugs 2008; 68(7): 913–24PubMedCrossRefGoogle Scholar
  12. 12.
    Grape S, Schug SA, Lauer S, et al. Formulations of fentanyl for the management of pain. Drugs 2010; 70(1): 57–72PubMedCrossRefGoogle Scholar
  13. 13.
    Electronic Medicines Compendium. Abstral sublingual tablets: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/21371/SPC/Abstral+Sublingual+Tablets/ [Accessed 2010 Oct 11]
  14. 14.
    ProStrakan Group. ProStrakan announces FDA acceptance of Abstral filing [media release]. 2009 Oct 6Google Scholar
  15. 15.
    Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53(1): 109–38PubMedCrossRefGoogle Scholar
  16. 16.
    Muijsers RBR, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289–307PubMedCrossRefGoogle Scholar
  17. 17.
    Hair PI, Keating GM, McKeage K. Transdermal matrix fentanyl membrane patch (Matrifen®): in severe cancer-related chronic pain. Drugs 2008; 68(14): 2001–9PubMedCrossRefGoogle Scholar
  18. 18.
    Narita M, Imai S, Itou Y, et al. Possible involvement of μ1-opioid receptors in the fentanyl- or morphine-induced antinociception at supraspinal and spinal sites. Life Sci 2002 Apr 5; 70(20): 2341–54PubMedCrossRefGoogle Scholar
  19. 19.
    Maguire P, Tsai N, Kamal J, et al. Pharmacological profiles of fentanyl analogs at mu, delta and kappa opiate receptors. Eur J Pharmacol 1992 Mar 24; 213(2): 219–25PubMedCrossRefGoogle Scholar
  20. 20.
    Bilfinger TV, Fimiani C, Stefano GB. Morphine’s immunoregulatory actions are not shared by fentanyl. Int J Cardiol 1998 Apr; 64 Suppl. 1: 61–6CrossRefGoogle Scholar
  21. 21.
    Rosow CE, Moss J, Philbin DM, et al. Histamine release during morphine and fentanyl anesthesia. Anesthesiology 1982; 56(2): 93–6PubMedCrossRefGoogle Scholar
  22. 22.
    Bovill JG. Which potent opioid? Important criteria for selection. Drugs 1987; 33: 520–30PubMedCrossRefGoogle Scholar
  23. 23.
    Megens AAHP, Artois K, Vermeire J, et al. Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J Pain Symptom Manage 1998; 15(4): 253–7PubMedCrossRefGoogle Scholar
  24. 24.
    Bredenberg S, Duberg M, Lennernas B, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci 2003; 20(3): 327–34PubMedCrossRefGoogle Scholar
  25. 25.
    Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomised phase II study. Palliat Med 2010 Apr; 24: 286–93PubMedCrossRefGoogle Scholar
  26. 26.
    Williams DA, Foye WO, Lemke TL. Foye’s principles of medicinal chemistry. 5th ed. Baltimore (MD): Lippincott Williams and Wilkins, 2002Google Scholar
  27. 27.
    Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005 Feb; 59(2): 249–53PubMedCrossRefGoogle Scholar
  28. 28.
    Lorch U, Farrell F, Kilborn J, et al. Pharmacokinetics and tolerability of sublingual fentanyl in healthy Japanese and Caucasian volunteers: phase I, open-label single-dose study. Proceedings of the 13th International Pain Clinic Congress; 2008 May 29–Jun 1; Seoul, 131–5Google Scholar
  29. 29.
    Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009 Oct 8; 25(12): 2877–85PubMedCrossRefGoogle Scholar
  30. 30.
    Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001 Jul; 15(4): 323–8PubMedCrossRefGoogle Scholar
  31. 31.
    Danjoux C, Franssen E, Chow E, et al. Sublingual fentanyl citrate for control of breakthrough pain in patients referred for palliative radiotherapy. Curr Oncol 2004; 11(1): 3–7Google Scholar
  32. 32.
    Nalamachu S, Howell J, Derrick R. Long-term safety and tolerability of sublingual fentanyl [poster]. American Academy of Pain Medicine 25th Annual Meeting; 2009 Jan 28–31; Honolulu (HI)Google Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations